Skip to content

Deficiency Of Beta Ureidopropionase C1291512

Published: July 22, 2026Updated: August 20, 2026

A rare genetic metabolic condition affecting how the body processes certain compounds. It typically appears in childhood. Management involves dietary modifications and monitoring, with outcomes varying by individual.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Developmental delay

(metabolic)

Fatigue or weight changes

(metabolic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Seizures

(metabolic)

Hypotonia

(metabolic)

Failure to thrive

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Pyrimidine-Restricted Diet

Reduction of dietary pyrimidine sources including organ meats, legumes, and certain vegetables decreases metabolite accumulation. Close collaboration with a metabolic dietitian ensures nutritional adequacy while limiting substrate availability.

dietary
3

Metabolic Parameter Tracking

Regular measurement of plasma and urinary pyrimidine metabolites, liver function tests, and neurological assessments. Imaging studies monitor for structural brain changes associated with metabolite accumulation.

monitoring

Additional treatment options

Symptomatic Pharmacological Management

Individualized medication regimens address specific manifestations such as anticonvulsants for seizure control and muscle relaxants for movement disorders. Treatment targets presenting symptoms rather than underlying enzymatic defect.

medication

Rehabilitative Exercise Program

Structured physical therapy maintains joint mobility, improves muscle strength, and supports functional independence. Aquatic therapy provides low-impact exercise suitable for patients with movement abnormalities.

physical_therapy

Neurodevelopmental Support

Cognitive assessment and educational support services address learning difficulties common in this metabolic disorder. Behavioral therapy helps manage impulse control issues and supports social development.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Deficiency Of Beta Ureidopropionase C1291512?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Van Kuilenburg AB, Dobritzsch D, Meijer J. Beta-ureidopropionase deficiency: clinical and molecular characterization. Orphanet J Rare Dis. 2020.

review2020
2

Sass JO, van Wegenberghe J, van Spronsen FJ. Clinical phenotype and biochemical findings in patients with beta-ureidopropionase deficiency. J Inherit Metab Dis. 2018.

clinical_trial2018
3

Häberle J, Burlina A, Chakrapani A, et al. Inherited metabolic disorders: European reference network for rare metabolic diseases - diagnostic and management guidelines. Mol Genet Metab. 2022.

guideline2022
4

Nassogne MC, Mavridou I, Makar G. Pyrimidine metabolism disorders. In:故Fernandes J, Saudubray JM, van den Berghe G, eds. Inborn Metabolic Diseases: Diagnosis and Treatment. 7th ed. Springer; 2021.

other2021

Medication Comparisons

Compare medications used to treat Deficiency Of Beta Ureidopropionase C1291512. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy